The Atamyo Therapeutics website is now accessible! Atamyo's mission is to provide a new generation of quality gene therapies for patients with neuromuscular diseases.
Currently, the pipeline focuses on 5 subtypes of LGMD:
- LGMD-R9 / LGMD2I
- LGMD-R5 / LGMD2C
- LGMD-R1 / LGMD2A
- LGMD-R2 / LGMD2B
- LGMD-R3 / LGMD2D
